Literature DB >> 19141860

Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia.

Dong Hwan Dennis Kim1, Wei Xu, Clement Ma, Xiangdong Liu, Katherine Siminovitch, Hans A Messner, Jeffrey H Lipton.   

Abstract

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder, characterized by the presence of BCR/ABL fusion gene. It is unclear which cellular events drive BCR/ABL gene translocation or initiate leukemogenesis in CML. Bcl-2 promotes survival of hematopoietic stem cells. Accordingly, apoptosis-related pathway may involve in the leukemogenesis of CML. In the current study, we evaluated 80 single nucleotide polymorphism (SNP) markers involved in the pathways of apoptosis (n = 30), angiogenesis (n = 7), myeloid cell growth (n = 14), xenobiotic metabolism (n = 13), WT1 signaling (n = 7), interferon signaling (n = 4), and others (n = 5) in 170 CML patients and 182 healthy controls. In a single-marker analysis, the following SNPs were identified including VEGFA, BCL2, CASP7, JAK3, CSF3, and HOCT1. In the multivariate logistic model with these SNPs and covariates, only BCL2 (rs1801018) was significantly associated with the susceptibility to CML (P = .05; odds ratio [OR] 2.16 [1.00-4.68]). In haplotype analyses, haplotype block of BCL2 consistently showed significant association with the susceptibility to CML. Risk allele analysis showed that a greater number of risk alleles from BCL2 SNP correlated to increasing risk of CML (overall P = .1, OR 1.84 [1.06-3.22] for 3-4 risk alleles vs 0-1 risk alleles). The current study indicated that BCL2 SNP seemed to be associated with increasing susceptibility to CML.

Entities:  

Mesh:

Year:  2009        PMID: 19141860     DOI: 10.1182/blood-2008-07-169110

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk.

Authors:  Jie Lin; Charles Lu; David J Stewart; Jian Gu; Maosheng Huang; David W Chang; Scott M Lippman; Xifeng Wu
Journal:  Carcinogenesis       Date:  2012-06-04       Impact factor: 4.944

2.  BCL2 genotypes: functional and neurobehavioral outcomes after severe traumatic brain injury.

Authors:  Nicole Zangrilli Hoh; Amy K Wagner; Sheila A Alexander; Robert B Clark; Sue R Beers; David O Okonkwo; Dianxu Ren; Yvette P Conley
Journal:  J Neurotrauma       Date:  2010-08       Impact factor: 5.269

Review 3.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

4.  Methylene tetrahydrofolate reductase (MTHFR) gene polymorphisms in chronic myeloid leukemia: an Egyptian study.

Authors:  Mervat Mamdooh Khorshied; Iman Abdel Mohsen Shaheen; Reham E Abu Khalil; Rania Elsayed Sheir
Journal:  Med Oncol       Date:  2013-12-13       Impact factor: 3.064

5.  Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk.

Authors:  I-Chen Wu; Yang Zhao; Rihong Zhai; Chen-yu Liu; Feng Chen; Monica Ter-Minassian; Kofi Asomaning; Li Su; Rebecca S Heist; Matthew H Kulke; Geoffrey Liu; David C Christiani
Journal:  Carcinogenesis       Date:  2011-01-06       Impact factor: 4.944

6.  Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder.

Authors:  Jochen Hess; Patrick Stelmach; Andreas Eisenhardt; Herbert Rübben; Henning Reis; Kurt Werner Schmid; Hagen Sjard Bachmann
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-17       Impact factor: 4.553

Review 7.  A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia.

Authors:  J E Megías-Vericat; M J Herrero; L Rojas; P Montesinos; V Bosó; F Moscardó; D Martínez-Cuadrón; J L Poveda; M Á Sanz; S F Aliño
Journal:  Pharmacogenomics J       Date:  2015-12-08       Impact factor: 3.550

8.  Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia.

Authors:  Rocio Sanchez; Janick St-Cyr; Marie-Eve Lalonde; Jasmine Healy; Chantal Richer; Vincent Gagné; Caroline Laverdière; Lewis B Silverman; Stephen E Sallan; Donna Neuberg; Jeffery L Kutok; Ekaterini A Kritikou; Maja Krajinovic; Daniel Sinnett
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

9.  High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients.

Authors:  Marc Delord; Philippe Rousselot; Jean Michel Cayuela; François Sigaux; Joëlle Guilhot; Claude Preudhomme; François Guilhot; Pascale Loiseau; Emmanuel Raffoux; Daniela Geromin; Emmanuelle Génin; Fabien Calvo; Heriberto Bruzzoni-Giovanelli
Journal:  Oncotarget       Date:  2013-10

10.  Genetic variation in BCL2 3'-UTR was associated with lung cancer risk and prognosis in male Chinese population.

Authors:  Ping Xu; Li Liu; Jianzhong Wang; Kai Zhang; Xiaohua Hong; Qifei Deng; Jingjun Xiang; Xiaomin Zhang; Meian He; Tangchun Wu; Huan Guo
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.